VSTM PDUFA decision: a negative outcome, -8.3%

On May 15, 2026, avutometinib (VS-6766) — Verastem, Inc. (Low Grade Ovarian Serous Adenocarcinoma) reached its PDUFA decision. The result was a negative outcome, and the stock moved -8.3% in the window around the event. It had already run -26.9% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.